Abstract
Transgender individuals are a growing patient population with unique dermatologic needs. Masculinizing hormone therapy (MHT) involves the use of exogenous testosterone to promote masculine and suppress feminine secondary sex characteristics.1 Commonly reported cutaneous effects of MHT include acne vulgaris and androgenic alopecia.2 To our knowledge, there have been no reported cases of hidradenitis suppurativa (HS) among transgender patients receiving MHT. Herein we present two patients, one that developed HS and one with worsening HS symptoms after initiating MHT.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
